<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="168263">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02020499</url>
  </required_header>
  <id_info>
    <org_study_id>A-9B-52030-265</org_study_id>
    <nct_id>NCT02020499</nct_id>
  </id_info>
  <brief_title>Predictive Factors Study</brief_title>
  <acronym>TAPAS</acronym>
  <official_title>Non-interventional, Observational, Long Term Study to Evaluate Common Therapeutic Algorithms and Possible Predictive Parameters for Somatuline Autogel (ATG) Treatment in Patients With Acromegaly.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a long term study to evaluate common therapeutic algorithms and possible predictive
      parameters for Somatuline Autogel treatment in patients with Acromegaly.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">February 2020</completion_date>
  <primary_completion_date type="Anticipated">February 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Observational</study_type>
  <study_design>Observational Model: Cohort, Time Perspective: Prospective</study_design>
  <primary_outcome>
    <measure>Change in Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels from baseline</measure>
    <time_frame>Baseline and 4 weeks</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Growth hormone (GH) and insulin-like growth factor-1 (IGF-1) levels from baseline</measure>
    <time_frame>Baseline, 1 year and 3 years</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">34</enrollment>
  <condition>Acromegaly</condition>
  <arm_group>
    <arm_group_label>Acromegalic patients</arm_group_label>
    <description>Acromegalic subjects treated with Somatuline Autogel® (Lanreotide)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Somatuline Autogel® (lanreotide) 60, 90, 120 mg.</intervention_name>
    <description>Patients receiving treatment as prescribed by the investigator and according to current treatment recommendations and routine clinical practice, and in line with local regulations.</description>
    <arm_group_label>Acromegalic patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Adult subjects in hospitals and private practices, suffering from acromegaly who are
        scheduled to receive ATG or already on treatment with ATG for a maximum of 3 months.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of Acromegaly.

          -  Males and females aged 18 years and older.

          -  Signed informed consent (patient must give consent to the collection of retrospective
             data).

          -  Patients who have had surgery may enter the study 3 months post-surgery and evaluated
             for the duration of the study.

          -  With the intention to be treated with ATG (decision to prescribe ATG made prior to
             inclusion into the study) or already being treated with ATG.

          -  If already being treated with ATG:

        Previous ATG treatment maximum of 3 months.  AND Minimum data available (demographic data,
        disease history including previous treatments, GH, IGF-1 levels at baseline and under
        treatment as applicable).

          -  Not receiving Dopamine Agonists or other medical therapy (Pegvisomant, or other
             somatostatin analogues) for the treatment or symptom control of acromegaly.

        Exclusion Criteria:

          -  The subject has had radiotherapy in the last 5 years.

          -  The subject has had surgery in the last 3 months.

          -  The subject has already been included in this study.

          -  Participation in an interventional trial, or receiving experimental drug.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mónica De Abadal, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ipsen Recruitment Enquiries</last_name>
    <email>clinical.trials@ipsen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane &amp; Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4006</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Princess Alexandra Hospital</name>
      <address>
        <city>Woolloongabba</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>St Vincent's Hospital</name>
      <address>
        <city>Fitzroy</city>
        <state>Victoria</state>
        <zip>3065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Austin Hospital</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <zip>3084</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 29, 2014</lastchanged_date>
  <firstreceived_date>December 19, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
